AllSci News
Basking's BB-025 rapidly reverses stroke thrombolytic in Phase I study
Phase I data from the Study of BB-025, Alone and After BB-031, in Healthy Volunteers show that BB-025, the oligonucleotide reversal agent for Research...
UC Irvine takes AI-powered metabolic imaging into drug resistance testing
University of California, Irvine has received a USD 3 million RC2 grant from the National Center for Advancing Translational Sciences (NCATS) to develop a...
Apollo's pan-rhinovirus vaccine triggers cross-species T cell responses in Phase I trial
A single dose of APL-10456, an adjuvanted recombinant protein subunit vaccine targeting rhinovirus, induced broad cross-reactive T cell responses against...
CDK8 emerges as potential disease-modifying target in osteoarthritis
Inhibiting a transcriptional kinase already explored in oncology can suppress the pathological cellular transition that drives cartilage breakdown in...
Moffitt researchers identify ULK3 dependency in multiple myeloma, report preclinical inhibitor efficacy
A serine/threonine kinase largely overlooked in myeloma biology drives autophagy-dependent tumor cell survival and proteasome inhibitor resistance,...
Anthropic's Claude autonomously designs protein binders against 14 of 15 targets
A large language model operating without human input into any individual design decision produced confirmed protein binders against 14 of 15 testable...
Japan approves Brinsupri as first treatment for non-cystic fibrosis bronchiectasis
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis (NCFB) in adults and...
Rhythm's Imcivree becomes first approved therapy for acquired hypothalamic obesity in Japan
Japan's Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization to Imcivree (setmelanotide) for acquired hypothalamic obesity...
Astellas pushes CLDN18.2 bispecific ASP2138 into Phase III
Astellas Pharma (TSE: 4503) has dosed the first patient in a Phase III trial of ASP2138, its subcutaneously administered CLDN18.2 × CD3 bispecific antibody,...
Antengene preps UCB-partnered CD19 bispecific TCE for first-in-human autoimmune testing in Oz
Australia has cleared ATG-201, Antengene Corporation Limited's (HKEX: 6996.HK) CD19 × CD3 bispecific T-cell engager (TCE), to enter first-in-human testing,...
FDA puts GSK’s Jemperli on priority review in locally advanced rectal cancer
The US FDA has accepted for priority review a supplemental Biologics License Application (sBLA) for dostarlimab (Jemperli), GSK's (LSE/NYSE: GSK)...
Japan approves GSK's Hibsago as first functional cure for chronic hepatitis B
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Hibsago (bepirovirsen) for chronic hepatitis B (CHB) in adults who have received at least...
Pfizer tests undisclosed immune-modulating asset across four autoimmune diseases
Pfizer (NYSE: PFE) has registered a Phase I/II clinical trial for PF-08154225, an immune-modulating agent of undisclosed mechanism, in patients with four...
FDA approves Imaavy as first treatment specifically indicated for wAIHA
The US FDA has approved Imaavy (nipocalimab-aahu) as the first therapy specifically indicated for warm autoimmune hemolytic anemia (wAIHA). Johnson &...
UCM and MIT research shows transient CB2R modulation locks breast cancer cells into less aggressive state
A brief pulse of cannabinoid receptor 2 (CB2R) activation is sufficient to lock breast cancer cells into a less aggressive, luminal-like identity that...
The AllSci Brief
Free, systematic R&D and deal news. Daily.